Literature DB >> 2570185

Carnitine deficiency induced by pivampicillin and pivmecillinam therapy.

E Holme1, J Greter, C E Jacobson, S Lindstedt, I Nordin, B Kristiansson, U Jodal.   

Abstract

Short-term administration of pivampicillin and pivmecillinam resulted in a reduction of serum carnitine concentration and an increase in excretion of acylcarnitine in urine. These changes persisted for more than ten days after cessation of therapy. In seven girls on long-term treatment with a mixture of pivampicillin and pivmecillinam the mean total serum carnitine concentration fell to 15% (7-27%) of pretreatment values. The acylcarnitine fraction was 11-57% of total carnitine, compared with less than 2% before treatment. Muscle carnitine concentrations in two girls treated with the antibiotics for 22 and 30 months were only 10% of the mean reference value. These concentrations in serum and muscle are in the range encountered in patients with carnitine deficiencies of other aetiologies in which life-threatening metabolic crises may arise. The risk of adverse effects from prodrugs that give rise to pivalic acid should be seriously considered, particularly in patients under metabolic stress.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570185     DOI: 10.1016/s0140-6736(89)92086-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  32 in total

Review 1.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

2.  Identification of mutations and evaluation of cardiomyopathy in Turkish patients with primary carnitine deficiency.

Authors:  M Kilic; R K Ozgül; T Coşkun; D Yücel; M Karaca; H S Sivri; A Tokatli; M Sahin; T Karagöz; A Dursun
Journal:  JIMD Rep       Date:  2011-09-22

3.  Inhibition of OCTN2-mediated transport of carnitine by etoposide.

Authors:  Chaoxin Hu; Cynthia S Lancaster; Zhili Zuo; Shuiying Hu; Zhaoyuan Chen; Jeffrey E Rubnitz; Sharyn D Baker; Alex Sparreboom
Journal:  Mol Cancer Ther       Date:  2012-03-02       Impact factor: 6.261

4.  Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid.

Authors:  Noboru Okamura; Shuichi Ohnishi; Hiroyuki Shimaoka; Ryo Norikura; Hiroshi Hasegawa
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 5.  Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency.

Authors:  Robert Ringseis; Janine Keller; Klaus Eder
Journal:  Eur J Nutr       Date:  2011-12-02       Impact factor: 5.614

Review 6.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

7.  [Decreased plasma carnitine in Type I diabetes mellitus].

Authors:  P Pregant; G Schernthaner; E Legenstein; L Lienhart; S Bruck; C Schnack; E Kaiser
Journal:  Klin Wochenschr       Date:  1991-08-16

8.  Induction of peroxisomal beta-oxidation and P-450 4A-dependent activities by pivalic and trichloroacetic acid in rat liver and kidney.

Authors:  U Zanelli; P Puccini; D Acerbi; P Ventura; P G Gervasi
Journal:  Arch Toxicol       Date:  1996       Impact factor: 5.153

9.  No effect of insulin treatment or glycemic improvement on plasma carnitine levels in type 2 diabetic patients.

Authors:  P Pregant; E Kaiser; G Schernthaner
Journal:  Clin Investig       Date:  1993-08

Review 10.  Carnitine transport: pathophysiology and metabolism of known molecular defects.

Authors:  I Tein
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.